AMGN240920P395000
- 72.14
- 0.000.00%
Amgen Newsroom
Behind the Scenes of Amgen's Latest Options Trends
Redburn Atlantic Adjusts Amgen Price Target to $200 From $180, Maintains Sell Rating
Dow's 335-Point Rally Led By Gains For Apple, Caterpillar Shares
10 Health Care Stocks With Whale Alerts In Today's Session
Amgen (AMGN) Stock Dips While Market Gains: Key Facts
Is Amgen Inc. (NASDAQ:AMGN) Trading At A 42% Discount?
Oppenheimer Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Oppenheimer analyst Jay Olson maintains $Amgen(AMGN.US)$ with a buy rating, and maintains the target price at $380.According to TipRanks data, the analyst has a success rate of 42.1% and a total
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Jefferies analyst Michael Yee maintains $Amgen(AMGN.US)$ with a buy rating, and maintains the target price at $380.According to TipRanks data, the analyst has a success rate of 43.3% and a total
Amgen (AMGN) Gets a Buy From Jefferies
This 'Forgotten Child' Is One of the Best Biotech Plays: Analyst
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024
Equitable Breakthroughs in Medicine Development (EQBMED) to Work With Inaugural Sponsor Companies to Drive Greater Diversity in Clinical Trials
Can Amgen Inc.'s (NASDAQ:AMGN) ROE Continue To Surpass The Industry Average?
UnitedHealth Follows Competitors, Replaces Humira With Lower-Cost Biosimilars
VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints
Dow Drops 400 Points On Losses For Shares Of UnitedHealth, Amgen
16 New GLP-1 Weight-loss Drugs Could Be Launched by 2029: Report
Tyra Biosciences Names Doug Warner Chief Medical Officer
Market Chatter: UnitedHealth Group to Exclude AbbVie's Humira From Some US Drug Reimbursement Lists